|Articles|January 27, 2014

EFGCP Broadens Support for Investigator-initiated Trials

Author(s)Philip Ward

The complex legal, regulatory, financial, and organizational requirements are not widely known...

The complex legal, regulatory, financial and organizational requirements are not widely known in the investigator, hospital and university communities engaged in clinical research, according the European Forum for GCP. To address the issue, it is running a two-day workshop, called Striving for Professionalism in Investigator-initiated trials (IITs), to be held in Brussels, Belgium, on February 26-27.

The legal conditions for academic sponsorship vary from country to country, which makes the organization of multinational trials even more difficult, noted a statement from EFGCP. Treatment optimization, exploration of new indications, head-to-head comparison of new medicines, investigation of long-term treatment outcomes and/or efficiency of treatments are important tasks for the medical community.

“Like for pharma company-initiated trials the overall responsibility for the trials lies also in IITs with the sponsor. But in contrast to privately sponsored studies the infrastructure to fulfil these sponsor obligations is not always available in an academic environment,” the organizers wrote.

The workshop aims to bring together investigators, academic organizations, hospital and university administration representatives, regulators, ethics committee members, lawyers, pharmaceutical companies, and patient representatives. The focus will be on different sponsor tasks and business models, contracting and training, and the aim is to produce recommendations for facilitating and harmonizing the framework and organization for IITs.


Related to this article

The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.